Senestech, Inc. (NASDAQ:SNES) is a clinical-stage medical technology company focused on the development and commercialization of non-invasive diagnostic and monitoring solutions for ocular surface diseases. Leveraging proprietary biosensor and digital analytics platforms, the company aims to provide eye care professionals with objective, quantitative data to improve the diagnosis and management of conditions such as dry eye disease. By integrating advanced sensor technology with cloud-based software, Senestech seeks to streamline clinical workflows, reduce diagnostic variability and enhance patient outcomes.
The company’s lead product, the TearSense® Analyzer, combines a wearable tear-collection sensor with an intuitive software interface that measures multiple biomarkers in real time. This platform is designed to detect key inflammatory proteins and osmolarity changes in the tear film, enabling early identification of dry eye subtypes and personalized treatment planning. In parallel, Senestech is advancing a next-generation smart contact lens prototype—VisionSense™—which aims to continuously monitor ocular physiology throughout the day, providing clinicians with longitudinal insights into disease progression and therapeutic efficacy.
Founded in 2015 as a spin-out from the University of Toronto’s Department of Biomedical Engineering, Senestech is headquartered in Cambridge, Massachusetts, with R&D operations in Ontario, Canada. The company has established strategic collaborations with leading academic centers and eye care device manufacturers to accelerate clinical validation and regulatory filings in North America, Europe and Asia. Senestech is actively pursuing CE marking and FDA 510(k) clearance for its TearSense® platform, positioning the company for initial commercial launch in key ophthalmology and optometry markets.
Led by Chief Executive Officer Dr. Michael Anderson, a veteran of the medical device industry, and Chief Technology Officer Dr. Emily Chen, an expert in ocular biomaterials, Senestech’s management team combines technical innovation with extensive regulatory and commercial experience. Under their guidance, the company has built a multidisciplinary leadership group encompassing clinical research, quality systems and global marketing. As Senestech approaches pivotal clinical milestones, it continues to strengthen its balance sheet through strategic financing and partnerships to support its goal of transforming dry eye diagnostics worldwide.
AI Generated. May Contain Errors.
Free SNES Stock Alerts